A Provider May Consider Testing for CYP2D6 Variants Prior to Starting

A provider may consider testing for CYP2D6 variants prior to starting tamoxifen for breast cancer to:

A) Ensure the patient will not have increased adverse drug reactions to the tamoxifen
B) Identify potential drug-drug interactions that may occur with tamoxifen
C) Reduce the likelihood of therapeutic failure with tamoxifen treatment
D) Identify poor metabolizers of tamoxifen